Chiron Recombinant Proteins

Company Headquarters

4560 Horton Street,
Emeryville, CA 94608
United States

View Phone No.

Visit Website

Company Description

VITAL STATISTICS

Commercial GMP production of FDA licensed recombinant proteins for over 30 years.

Located in the SF Bay Area with laboratories, pilot plant, and GMP manufacturing facilities for microbial and mammalian processes

As a division of Grifols, Chiron Recombinant Proteins is a CDMO partnering with companies developing complex proteins into therapeutics, vaccines and diagnostics.

WHO WE ARE

The biomanufacturing legacy of the Grifols campus in Emeryville, California, began with Chiron and Cetus in the 1980s, with innovative advancements in yeast expression, viral discovery and the development of PCR. Three decades of process development and GMP manufacturing experience is the foundation of the business today.

Grifols acquired the Emeryville site in 2014 from Novartis. Reflecting the impact of Chiron’s science-first legacy on Grifols’ proven, business-driven CDMO model, Grifols CDMO relaunched as Chiron Recombinant Proteins in 2021. Chiron is the partner of choice for companies seeking innovation, capability and flexibility.

CHIRON® Recombinant Proteins is staffed by highly experienced and talented people with diverse expertise and educational backgrounds within the field of biotechnology. We welcome the opportunity to have face-to-face visits with clients where new ideas can be discussed. With their significant tech transfer expertise and access to the state-of-the-art facilities and equipment within the CMF, pilot plant and analytical laboratories, our scientists can rapidly identify solutions for our CDMO clients.

MAJOR MARKETS

Our state-of-the-art GMP biological manufacturing facility located in the San Francisco Bay Area is well positioned to provide long-term, high-quality, commercial manufacturing of recombinant biologic drug substances to our customers, regardless of their global location.

SERVICES OFFERED

Services: Tech transfer, process development, process characterization, analytical development, analytical qualification/validation, process validation, GMP and non-GMP production of drug substance

Stages: Research, pre-clinical, clinical, commercial

Production scale: 10L, 250L and 300L microbial stainless steel and single-use fermenters; 10L, 200L and 1,000L mammalian single-use bioreactors

Hosts: E.coli, Saccharomyces, Pichia, CHO, HEK293

Contract Services Directory

Analytical Methods Development

Biologics Manufacturing

Biologics Process Development

Cell Line Construction & Development

Contract Development and Manufacturing Organization (CDMO)

Contract Manufacturing

Custom Manufacturing

Downstream Processing

Fermentation

Mammalian Cell Culture

Manufacturing, Biologics

Manufacturing, Custom

Manufacturing, Microbial-based Therapeutic Proteins

Manufacturing, Proteins

Methods Development

Methods Validation

Microbial Fermentation

Process Characterization

Process Development/Scale-Up Services

Process Validation Studies

Protein Extraction/Purification

Purification

Technology Transfer

Content From Chiron Recombinant Proteins

cGMP Manufacture | Drug Development | Process Development

Recombinant Proteins: Understanding 5 Key Process Development Challenges

It is important to ensure process elements like scalability, sourcing raw materials, and GMP adherence are considered during process development.

White Papers / Tech Papers Released on 02.10.2023
Bringing Your Vision to Life

Process Development to GMP Manufacturing

Literature / Brochures Released on 12.02.2022
Mammalian Cell Culture Manufacturing

Reserve your space now for Clinical and Commercial Mammalian cGMP manufacturing

Literature / Brochures Released on 12.02.2022
Optimizing CDMO Technical Transfer

A CDMO helps organizations predict and mediate technical transfer risks for a successful project start.

White Papers / Tech Papers Released on 12.01.2022
Growing With A Flexible, Collaborative CDMO

When selecting a CDMO, companies typically place the greatest emphasis on price, quality and capabilities, but do not always appropriately weigh other factors.

Literature / Brochures Released on 12.01.2022
New Facility Presents Manufacturing Solutions For Recombinant Proteins

Grifols' $80 million consolidated manufacturing facility (CMF) is located in Emeryville, California.

Literature / Brochures Released on 12.01.2022
Innovation and Flexibility Drive Success During the COVID-19 Pandemic

In these exceptional circumstances, what we do matters more than ever.

Company Blog Released on 12.01.2022
Leveraging a Biomanufacturing Legacy to Support New Business

A sit down with six diverse experts at Grifols Recombinant Protein CDMO.

Literature / Brochures Released on 12.01.2022
Improve Biopharmaceutical Fermentation With An Innovative, Collaborative Approach

Process development is a crucial stage in biopharmaceutical manufacturing.

White Papers / Tech Papers Released on 11.30.2022
Solving Process Challenges Requires Flexibility To Explore Alternative Analytical Methods

Successful and rapid analytical method development plays a key role in ensuring the development of robust processes to produce high-quality products.

Case Studies Released on 11.30.2022
Quality Assurance And Your CDMO

It’s no longer just a cost of doing business; your outsourced manufacturing partner’s approach to QA can save you money and reduce time to market.

Literature / Brochures Released on 11.30.2022
Grifols Achieves Key Milestone with FDA Approval of New CMF for Production of Recombinant Proteins

The new facility, equipment, and automation systems ensure reliable production of antigens for blood supply safety and patient health.

News Releases Released on 11.30.2022

Login

Join

FOLLOW:

Subscribe Free

Magazine

eNewsletter

Checkout